South Africa has officially entered a new phase in its HIV prevention strategy with the nationwide introduction of Lenacapavir, an injectable medication administered just twice a year to reduce the risk of HIV transmission. The rollout was formally inaugurated today at Lilian Ngoyi Stadium in Secunda, Mpumalanga, with President Cyril Ramaphosa and Health Minister Dr Aaron Motsoaledi presiding over the ceremony.
From Promise to Practice
The deployment of Lenacapavir fulfills a pledge President Ramaphosa made during his February 2026 State of the Nation Address. At that time, he committed to a large-scale distribution of the six-monthly injection, emphasizing its strong clinical evidence for preventing HIV transmission. According to a pre-launch advisory from the Presidency, this initiative represents a pivotal advancement in South Africa’s sustained campaign against HIV/AIDS and is designed to strengthen efforts to curb new infections.
The rollout exemplifies a unified approach, bringing together government institutions, civil society organizations, private industry, and international development partners—all aligned toward the shared objective of eliminating HIV as a public health concern in South Africa.
Honoring Legacy, Building Progress
The timing of the launch carries symbolic weight, arriving shortly after the anniversary of the death of youth HIV/AIDS advocate Nkosi Johnson, who passed away on 1 June 2001 at just 12 years old. His enduring influence continues to galvanize action across the continent.
This development also builds upon South Africa’s 2010 launch of the world’s most extensive HIV counselling, testing, and treatment initiative. That foundational campaign has contributed to significant health improvements. Per the Department of Health’s 2026 Budget Vote, national life expectancy has climbed to 66.9 years as of 2025, up from 54 years in 2010. Additionally, maternal mortality declined to 89 deaths per 100,000 live births by 2020, down sharply from 240 per 100,000 in 2010.
Understanding the Current Epidemic
While progress is evident, HIV remains a critical health priority. Statistics South Africa’s Mid-Year Population Estimates for 2025 report that approximately 8.15 million South Africans are living with HIV, representing roughly 12.9% of the nation’s estimated 63.1 million people. Within the most impacted demographic—adults aged 15 to 49—the prevalence rate is estimated at 18.1%.
Despite these figures, the same report highlights that expanded access to treatment and care has driven a measurable decline in HIV- and AIDS-related mortality.
Strategic Distribution and Targeted Access
Minister Motsoaledi, in his recent Budget Vote address, confirmed that Lenacapavir supplies are currently being transported to regional depots and healthcare facilities. The initial implementation will prioritize 360 health facilities situated in districts with the highest HIV burden.
Priority populations for early access include:
- Adolescent girls and young women aged up to 24 years
- Pregnant and breastfeeding individuals
- Female sex workers
- Men who have sex with men
- Transgender persons
- People who use injectable drugs
The first shipment—comprising 37,920 doses—arrived in South Africa in early April 2026. Lenacapavir is classified as a novel, long-acting antiretroviral agent and functions specifically as an HIV-1 capsid inhibitor.
Prevention, Not Vaccination
Health authorities have clarified that Lenacapavir is a preventive pharmaceutical, not a vaccine. Its extended-release formulation addresses several limitations associated with daily oral PrEP (pre-exposure prophylaxis), offering users enhanced privacy, reduced dosing frequency, and potentially stronger adherence—particularly for those who find daily pill regimens or regular clinic visits challenging.
The South African National AIDS Council (SANAC), which celebrated the drug’s arrival in April, stated this week that the launch marks a “new chapter in HIV prevention.”
Regulatory Leadership and Global Alignment
South Africa demonstrated regulatory leadership when the South African Health Products Regulatory Authority (SAHPRA) granted approval for Lenacapavir on 27 October 2025—the first such authorization by any African regulatory body. Subsequently, the World Health Organization (WHO) incorporated the injectable into its HIV prevention guidelines, recommending it as an additional prevention option. Importantly, WHO guidance notes that Lenacapavir does not need to be stopped during pregnancy or breastfeeding for HIV-negative women who face a high risk of HIV exposure.
This national milestone aligns with renewed global focus on HIV/AIDS. The United Nations General Assembly will convene a High-Level Meeting on AIDS on 22–23 June 2026 in New York. Held every five years since 2001, this forum serves as the UN’s principal political platform for accountability and commitment in the worldwide HIV response. The 2026 session will assess progress since the 2021 High-Level Meeting and draft a new UN Political Declaration on HIV and AIDS, with Member States negotiating and considering adoption of the final text. South Africa participates actively as a UN Member State.
UNAIDS South Africa recently shared via social media platform X that it is “excited” to join President Ramaphosa, the Department of Health, SANAC, and other partners for today’s launch event.
Complementary National Efforts
Lenacapavir’s introduction complements broader government strategies, including the February 2025 launch of the Close the Gap campaign. Developed alongside WHO, UNAIDS, and additional stakeholders, this focused, multi-pronged initiative aims to accelerate South Africa’s HIV response by concentrating resources on high-burden districts, communities, and health facilities. It places particular emphasis on underserved and vulnerable groups—including men, youth, children, and key populations—to improve HIV-related outcomes and address persistent service gaps.
A Shared Vision for the Future
Minister Motsoaledi expressed measured confidence about the path ahead, stating that South Africa has reached a point “where we dare say we can eliminate HIV/AIDS as a public health threat.” He concluded with a unifying call to action: “All we have to do is to work hard and work hard together as South Africans motivated and bound together by a common destiny.”
With Lenacapavir now available as part of the national prevention portfolio, South Africa advances toward that collective vision—expanding options, empowering communities, and reinforcing momentum in the ongoing effort to end the HIV epidemic.